Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects - Concepedia

Concepedia

Publication | Closed Access

Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects

15

Citations

12

References

2009

Year

G. Carosi, Adriano Lazzarin, Hans‐Juergen Stellbrink, Graeme Moyle, Sorin Rugină, Schlomo Staszewski, Naomi Givens, Lisa Ross, Catherine Granier, Mounir Ait‐Khaled,

HIV Clinical Trials

Abstract

Though the study did not continue to stage 2, fosamprenavir/ritonavir once daily demonstrated noninferior antiviral efficacy to fosamprenavir/ritonavir twice daily.

References

	Year	Citations

Page 1